AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16802519
Drug: Beta-blockers, ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers, ACE inhibitors/AT1 receptor antagonists, diuretics, aldosterone antagonists, and glycosides (specific dosages and durations not available)
Trial: 14581346
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg rofecoxib once a day for 9 months
Trial: 14581346
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg rofecoxib once a day
Trial: 10947698
Drug: Caudal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal ropivacaine 0.2% 1 ml/kg
Trial: 10947698
Drug: Caudal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal ropivacaine 0.2% 1 ml/kg plus caudal ketamine 0.25 mg/kg
Trial: 9224783
Drug: [14C]avitriptan 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [14C]avitriptan 20 mg/kg iv and oral in rats; 10 mg iv and 50 mg oral in humans
Trial: 30124733
Drug: Nature-based regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nature-based regimen (NR) containing natural oils, beeswax, and witch hazel, and day & night creams containing natural oils, glycerin, and botanical anti-inflammatories
Trial: 30124733
Drug: Synthetic dermatologist-recommended
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic dermatologist-recommended regimen (CR) containing cetyl alcohol, sodium lauryl sulphate-containing cleanser and glycerin, polyisobutene-containing lotion
Trial: 20819314
Drug: Subcutaneous IFN-gamma
RxNorm normalized name: IFN-gamma 1b
DrugBank: Interferon gamma-1b (DB00033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IFN-gamma injection
Trial: 3138441
Drug: BCAA-enriched amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA-enriched amino acid solution
Trial: 27768643
Drug: Transcanalicular laser‐assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcanalicular laser‐assisted dacryocystorhinostomy with endonasal augmentation without intubation
Trial: 27768643
Drug: Transcanalicular laser‐assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcanalicular laser‐assisted dacryocystorhinostomy with endonasal augmentation with bicanalicular intubation
Trial: 22311378
Drug: Kava (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kava (180 mg of kavalactones)
Trial: 19452698
Drug: Sertraline hydrochloride
RxNorm normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline hydrochloride tablets for 24 weeks
Trial: 11726450
Drug: 0.125% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine plus 0.5 microg/mL sufentanil (BS group)
Trial: 11726450
Drug: 0.125% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% ropivacaine plus 0.5 microg/mL sufentanil (RS group)
Trial: 8478307
Drug: Dirithromycin 500
RxNorm normalized name: Dirithromycin
DrugBank: Dirithromycin (DB00954)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dirithromycin 500 mg once daily for 7 days
Trial: 8478307
Drug: Erythromycin 250
RxNorm normalized name: erythromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 250 mg four times daily for 7 days
Trial: 8478307
Drug: Dirithromycin 500
RxNorm normalized name: Dirithromycin
DrugBank: Dirithromycin (DB00954)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dirithromycin 500 mg once daily for 7 days (European study)
Trial: 8478307
Drug: Dirithromycin 500
RxNorm normalized name: Dirithromycin
DrugBank: Dirithromycin (DB00954)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dirithromycin 500 mg once daily for 7 days (Italian study)
Trial: 8478307
Drug: Miocamycin 600
RxNorm normalized name: miocamycin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miocamycin 600 mg twice daily for 7 days (Italian study)
Trial: 28520754
Drug: IWT +
RxNorm normalized name: Ibuprofen and Tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IWT + high-dose post-exercise milk product intake (HD, n = 13)
Trial: 28520754
Drug: IWT +
RxNorm normalized name: Ibuprofen and Tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IWT + low-dose post-exercise milk product intake (LD, n = 12)
Trial: 26171983
Drug: Intranasal 8
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 8 IU OT
Trial: 26171983
Drug: Intranasal 24
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 24 IU OT
Trial: 26171983
Drug: Intravenous 1
RxNorm normalized name: fat emulsion, intravenous 10% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 1 IU OT
Trial: 19566638
Drug: Support program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Support program for stress management (homework for 3 months, nurse feedback monthly)
Trial: 17513626
Drug: Caudal clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caudal clonidine (2 mcg/kg) combined with 1.0 mL/kg of 0.2% ropivacaine with epinephrine
Trial: 17513626
Drug: Caudal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal morphine (50 mcg/kg) combined with 1.0 mL/kg of 0.2% ropivacaine with epinephrine
Trial: 17513626
Drug: Caudal hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal hydromorphone (10 mcg/kg) combined with 1.0 mL/kg of 0.2% ropivacaine with epinephrine
Trial: 15593020
Drug: Methylprednisolone with
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone with chlorambucil or cyclophosphamide (6-month treatment alternating every other month)
Trial: 15593020
Drug: Long acting
RxNorm normalized name: Long Acting Nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long acting ACTH preparation (1 year treatment)
Trial: 9931685
Drug: Intravenous glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous glutamine substitution
Trial: 11035984
Drug: Progesterone and
RxNorm normalized name: progesterone and estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone and progestins; specific dosage and duration not mentioned.
Trial: 11035984
Drug: Estrogen; specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen; specific dosage and duration not mentioned.
Trial: 8933313
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g daily with 1 g probenecid)
Trial: 8933313
Drug: Cefazolin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (2 g daily with 1 g probenecid)
Trial: 29134744
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium propionate (6845 mg)
Trial: 29134744
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride (4164 mg)
Trial: 22767424
Drug: Any treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any treatment preference
Trial: 22767424
Drug: Medication only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication only preference
Trial: 22767424
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment preference
Trial: 20039429
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: mycophenolate mofetil (target dosage 3 gm/day)
Trial: 20039429
Drug: intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous cyclophosphamide (0.5‐1.0 gm/m(2)/month)
Trial: 15333078
Drug: Oral d,l‐sotalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral d,l‐sotalol (196 +/- 42 mg/day for 7 days)
Trial: 15333078
Drug: Oral d,l‐sotalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral d,l‐sotalol (216 +/- 51 mg/day)
Trial: 11605744
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) in adherent PBMC group (n = 20)
Trial: 11605744
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) in total PBMC group (n = 9)
Trial: 8085482
Drug: Structured Learning
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured Learning Therapy (SLT)
Trial: 2665639
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate (23 mg of elemental zinc lozenges taken every 2 hours)
Trial: 2665639
Drug: Placebo (taste-matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (taste-matched sucrose octaacetate lozenges)
Trial: 25923550
Drug: Rociletinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rociletinib (500 mg to 1000 mg twice daily)
Trial: 23889096
Drug: Liquid formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulation of benazepril (0.45 mg/kg daily for 4 days)
Trial: 23889096
Drug: Tablet formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet formulation of benazepril (0.45 mg/kg daily for 4 days)
Trial: 21742089
Drug: Routine PCI
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine PCI with standard-of-care medical therapy
Trial: 12074359
Drug: Omapatrilat (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omapatrilat (40 mg)
Trial: 8924548
Drug: Theophylline 300
RxNorm normalized name: theophylline 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline 300 mg twice a day (E1)
Trial: 8924548
Drug: Salbutamol 4
RxNorm normalized name: Salbutamol 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 4 mg tid (E2)
Trial: 8924548
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Theophylline 200 mg and Salbutamol 4 mg (E3)
Trial: 8924548
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Theophylline 100 mg and Salbutamol 2 mg (E4)
Trial: 8924548
Drug: Placebo calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo calcium lactate 300 mg tid (E5)
Trial: 27932240
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream once daily (superficial basal cell carcinoma, 6 weeks; nodular basal cell carcinoma, 12 weeks)
Trial: 27932240
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream once daily
Trial: 25216962
Drug: EMLA patches
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA patches on all abdominal incisions
Trial: 25216962
Drug: Placebo patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patches on all abdominal incisions
Trial: 12586130
Drug: Warfarin (INR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (INR 2.8-4.2)
Trial: 18474393
Drug: Aspirin 75
RxNorm normalized name: aspirin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 75 mg/d and Warfarin (INR 2.0-2.5)
Trial: 23130135
Drug: Aspirin 160
RxNorm normalized name: aspirin 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 160 mg/d
Trial: 11795688
Drug: cream with
RxNorm normalized name: CREAM WITH APPLICATOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cream with phytoestrogens
Trial: 11795688
Drug: placebo (cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (cold cream)
Trial: 9709785
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron supplementation (285.6 mg of elemental iron/day)
Trial: 9709785
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron plus intravenous iron supplementation (285.6 mg of elemental iron/day orally plus 102.5 mg of elemental iron/week intravenously)
Trial: 8071390
Drug: 600‐mg methocel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600‐mg methocel tablet (sustained-release)
Trial: 8071390
Drug: 300‐mg CAP/carbovax-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300‐mg CAP/carbovax-coated tablet (immediate-release)
Trial: 8071390
Drug: 600‐mg sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600‐mg sustained-release tablet
Trial: 8071390
Drug: 300‐mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300‐mg tablet b.i.d.
Trial: 29766748
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) enriched 5% oil formulation with 0.25% δ‐9‐tetrahydrocannabinol (THC) 20:1
Trial: 29766748
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) enriched 5% oil formulation with 0.83% THC 6:1
Trial: 26617135
Drug: Parenteral Nutritional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral Nutritional Support (PN)
Trial: 18787350
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel at a dose of 100 mg/m(2) plus radiotherapy (group I)
Trial: 16969042
Drug: Gemcitabine; specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine; specific dosage and duration not mentioned
Trial: 10218338
Drug: Surfactant therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant therapy using the INSURE approach (Intubation‐SURfactant‐Extubation)
Trial: 2006722
Drug: Propofol 10
RxNorm normalized name: propofol 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 10 mg kg‐1 h‐1
Trial: 6216344
Drug: Piperacillin (181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin (181 mg/kg intravenous daily for 6 days)
Trial: 6216344
Drug: Carbenicillin (270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenicillin (270 mg/kg intravenous daily for 6 days)
Trial: 17575485
Drug: Granisetron injection
RxNorm normalized name: granisetron Injection
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron injection
Trial: 14752215
Drug: Butterbur root
RxNorm normalized name: butterbur root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butterbur root extract (Petadolex), 25 mg, two capsules twice a day
Trial: 11822760
Drug: Nolatrexed 725
RxNorm normalized name: Nolatrexed
DrugBank: Nolatrexed (DB12912)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nolatrexed 725 mg/m2 per day (5-day continuous infusion every three weeks)
Trial: 11822760
Drug: Methotrexate 40
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 40 mg/m2 weekly (short infusion)
Trial: 8209058
Drug: Capsaicin inhalation
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin inhalation (3.33 x 10(‐4) M)
Trial: 27494094
Drug: Neck-specific training
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neck-specific training in combination with a cognitive behavioural approach
Trial: 25282031
Drug: CoQ10 100
RxNorm normalized name: Walgreens CoQ10 100mg Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 100 mg 3 times daily
Trial: 19607755
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nefazodone and Cognitive Behavioral Analysis System of Psychotherapy
Trial: 16477764
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (200 mg daily for 15 months)
Trial: 12189442
Drug: L-arginine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine infusion (3 g in 10 ml saline)
Trial: 1955626
Drug: 12 tablets
RxNorm normalized name: nylon 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 tablets of the supplement a day for three menstrual cycles
Trial: 1955626
Drug: 6 tablets
RxNorm normalized name: ALLANTOIN 66 mg in 600 mg VAGINAL TABLET [Jilgyungyi (6 Tablets)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 tablets of the supplement a day for three menstrual cycles
Trial: 23026843
Drug: Clopidogrel besylate
RxNorm normalized name: Clopidogrel besylate
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel besylate 75 mg
Trial: 17899308
Drug: Cevimeline hydrochloride
RxNorm normalized name: Cevimeline Hydrochloride
DrugBank: Cevimeline (DB00185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cevimeline hydrochloride 30 mg three times per day for 10 weeks
Trial: 16871247
Drug: Fosinopril 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril 5 mg titrated to 20 mg daily
Trial: 10937676
Drug: Tamoxifen (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (higher doses proposed, at least four to eight-fold that of the dose efficacious in an oestrogen-receptor dependent mechanism)
Trial: 1431597
Drug: Psyllium (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium (15 g/day for 40 days)
Trial: 3883690
Drug: PGE2 gel
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 gel (Prostaglandin E2)
Trial: 30368585
Drug: BNC105P 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNC105P 12 mg/m2 with gemcitabine 1000 mg/m2 and carboplatin AUC4
Trial: 30368585
Drug: BNC105P 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNC105P 16 mg/m2 (maintenance treatment)
Trial: 30368585
Drug: BNC105P 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNC105P 800 mg/m2 with gemcitabine and carboplatin AUC4
Trial: 30368585
Drug: BNC105P 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNC105P 1000 mg/m2 with gemcitabine and carboplatin AUC4
Trial: 29359856
Drug: Flumazenil injection
RxNorm normalized name: Flumazenil Injection
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flumazenil injection administered i.v. 10 min after transfer to recovery room
Trial: 29359856
Drug: Flumazenil injection
RxNorm normalized name: Flumazenil Injection
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flumazenil injection
Trial: 24925094
Drug: True needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: True needle acupuncture for ten treatments over eight weeks
Trial: 24925094
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture with non‐insertive (blunt) needles for ten treatments over eight weeks
Trial: 23101480
Drug: Rituximab in
RxNorm normalized name: rituximab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab in addition to standard treatment with steroid-boli
Trial: 23101480
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment alone (placebo)
Trial: 19701637
Drug: Tocilizumab, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab, administered in a clinical setting, dosage not specified, duration of treatment not specified.
Trial: 17681004
Drug: Gaviscon Advance
RxNorm normalized name: Gaviscon
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaviscon Advance (10 ml)
Trial: 17681004
Drug: New tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New tablet product containing the same active ingredients as Gaviscon Advance
Trial: 17681004
Drug: Control (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (10 ml water)
Trial: 9682114
Drug: Heparin-surface-modified (HSM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-surface-modified (HSM) convex-plano laser-ridge IOL
Trial: 2113492
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone agonist (GnRH-a) and hMG; 38 cycles
Trial: 360842
Drug: Clotrimazole 1
RxNorm normalized name: clotrimazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole 1 per cent vaginal cream for 7 days
Trial: 360842
Drug: Miconazole nitrate
RxNorm normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole nitrate 2 per cent vaginal cream for 14 days
Trial: 29178758
Drug: Mg(OH)2 dentifrice
RxNorm normalized name: Magnesium, ion(Mg2+)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg(OH)2 dentifrice
Trial: 17296460
Drug: Imidapril (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidapril (up to 20 mg/d)
Trial: 17296460
Drug: Candesartan (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (up to 16 mg/d)
Trial: 8544215
Drug: Oral suspension
RxNorm normalized name: Oral Suspension
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral suspension of antibiotic-resistant Bifidobacterium longum for 30 days, commencing 10-12 days post-irradiation.